

This Month in the Journal

- 1297 Thalassaemia major: the iron irony
Rachel Stenner
- 1297 Immune surveillance of leukemia?
David A. Scheinberg
- 1298 Synthetic peptide analogs derived from BCR/ABL fusion proteins induce heteroclitic human T-cell responses
Masaki Yasukawa
- 1298 Pegylated interferon for the treatment of high risk essential thrombocythemia
Ruben Mesa
- 1298-1299 Outcome after allogeneic bone marrow transplantation in cytogenetic high-risk myelodysplastic syndromes and acute myeloid leukemia
Matteo Giovanni Della Porta, Luca Malcovati
- 1299-1300 Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia
Renato Bassan
- 1300 Bendamustine in relapsed or refractory chronic lymphocytic leukemia
Alessandra Ferrajoli
- 1300-1301 Minimal residual disease detection in myeloma: no more molecular remissions?
Andy C. Rawstron
- 1301 Chimerism analysis after allogeneic stem cell transplantation
Martin Bornhauser, Christian Thiede
- 1301-1302 Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary disease following allografting
David A. Jacobsen
- 1302 CD25 expression on donor CD8⁺ T cells and graft-versus-host disease
Mohamad Mohty
- 1302 Hepatic veno-occlusive disease following stem cell transplantation: young patients are not sheltered from this complication
Alessandro Busca
- 1303 T time
Jane E. Barker
- 1303 Gene transfer of HA-1 specificity
Rita Maccario

Editorials and Perspectives

- 1304-1305 Combined therapy with deferiprone and desferrioxamine in thalassaemia major
Dimitrios Loukopoulos
- 1305-1308 Evaluation and monitoring of response to therapy in multiple myeloma
S. Vincent Rajkumar, Angela Dispenzieri

Research Papers

- 1309-1314 *Thalassaemia major*
Combined therapy with deferiprone and desferrioxamine in thalassaemia major
Raffaella Origa, Patrizio Bina, Annalisa Agus, Gabriella Crobu, Elisabetta Defraia, Carlo Dessi, Giovan Battista Leoni, Pier Paolo Mironi, Renzo Galanello
- 1315-1323 *Chronic Myeloid Leukemia*
Circulating bcr-abl-specific CD8⁺ T cells in chronic myeloid leukemia patients and healthy subjects
Nauman M. Butt, José M. Rojas, Libui Wang, Stephen E. Christmas, Hazem M. Abu-Eisha, Richard E. Clark
- 1324-1332 *Chronic Myeloid Leukemia*
Synthetic peptide analogs derived from bcr-abl fusion proteins and the induction of heteroclitic human T-cell responses
Javier Pinilla-Ibarz, Tatyana Korontsvit, Victoriya Zakhaleva, Wendy Roberts, David A. Scheinberg
- 1333-1338 *Chronic Myeloproliferative Disorders*
Pegylated interferon for the treatment of high-risk essential thrombocythemia: results of a phase II study
Christian Langer, Eva Lengfelder, Jürgen Thiele, Hans M. Kvasnicka, Heike L. Pahl, Barbara Stade, Heimo Beneke, Stefanie Schauer, Heinz Gisslinger, Martin Griesshammer
- 1339-1345 *Acute Myeloid Leukemia*
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome having chromosome 5 and/or 7 abnormalities
Hanneke M. van der Straaten, Anja van Biezen, Ronald Brand, Anton V.M.B. Schattenberg, Roel M. Egeler, Renée M. Barge, Jan J. Cornelissen, Harry C. Schouten, Gert J. Ossenkoppele, Leo F. Verdonck on behalf of the Netherlands Stem Cell Transplant Registry "TYPHON"
- 1346-1356 *Acute Lymphoblastic Leukemia*
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial
Josep-Maria Ribera, Albert Oriol, Concepción Bethencourt, Ricardo Parody, Jesús-Maria Hernández-Rivas, María-José Moreno, Eloy del Potro, Mar Tormo, Concepción Rivas, Joan Besalduch, Miguel-Angel Sanz, Juan-José Ortega on behalf of PETHEMA Group, Spain
- 1357-1364 *Chronic Lymphoproliferative Disorders*
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
Manuela A. Bergmann, Maria E. Goebeler, Michael Herold, Bertold Emmerich, Corinna Ruelfs, Lothar Boening, Michael J. Hallek for the GCLLSG
- 1365-1372 *Multiple Myeloma*
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry
María Eugenia Sarasquete, Ramón García-Sanz, David González, Joaquín Martínez, Gema Mateo, Pilar Martínez, José María Ribera, José Mariano Hernández, Juan José Lahuerta, Alberto Orfão, Marcos González, Jesus Fernando San Miguel

- Stem Cell Transplantation**
1373-1379 A comparison of fluorescent *in situ* hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation
Ismael Buño, Paola Nava, Ainhoa Simón, Milagros González-Rivera, José Luis Jiménez, Pascual Balsalobre, David Serrano, Rafael Carrión, Alfonso Gómez-Pineda, José Luis Díez-Martín
- Stem Cell Transplantation**
1380-1388 Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia
Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Mee Seol, Young-Shin Lee, Seong-Gil Ryu, Chan-Jeoung Park, Hyun-Sook Chi, Moo-Song Lee, SungCheol Yun, Jung-Shin Lee, Kyoo-Hyung Lee
- Stem Cell Transplantation**
1389-1395 The association of CD25 expression on donor CD8⁺ and CD4⁺ T cells with graft-versus-host disease after donor lymphocyte infusions
Tuna Mutis, Tineke Aarts-Riemens, Leo F. Verdonck
- Stem Cell Transplantation**
1396-1404 A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
Simone Cesaro, Marta Pillon, Enrico Talenti, Tiziana Toffolutti, Elisabetta Calore, Gloria Tridello, Liliana Strugo, Roberta Destro, Maria Vittoria Gazzola, Stefania Varotto, Gabriella Errigo, Modesto Carli, Luigi ZanESCO, Chiara Messina
- Stem Cell Transplantation**
1405-1414 *In vitro* and *in vivo* T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation
Markus G. Seidel, Gerhard Fritsch, Susanne Matthes-Martin, Anita Lawitschka, Thomas Lion, Ulrike Pötschger, Agathe Rosenmayr, Gottfried Fischer, Helmut Gadner, Christina Peters
- Cell Therapy and Immunotherapy**
1415-1421 Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer
Bregje Mommaas, Astrid G.S. van Halteren, Jos Pool, Lars van der Veken, Brigitte Wieles, Mirjam H.M. Heemskerk, Els Goulmy

Decision Making and Problem Solving

- Malignant Lymphomas**
1422-1432 Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma
Michel van Agthoven, Mark H.H. Kramer, Pieter Sonneveld, Klaas G. van der Hem, Peter C. Huijgens, Pierre W. Wijermans, Hanneke C. Kluin-Nelemans, M. Ronald Schaafsma, Douwe H. Biesma, Vera Mattijssen, Carin A. Úyl-de Groot, Anton Hagenbeek

Letters to the Editor

- Malignant Lymphomas**
1433-1434 Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
Susanne Hipp, Ingo Ringshausen, Madlene Oelsner, Christian Bogner, Christian Peschel, Thomas Decker
- Lymphoproliferative Disorders**
1435-1436 The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53
Nnenna C. Osuji, Ilaria Del Giudice, Estella Matutes, Andrew C. Wotherspoon, Claire Dearden, Daniel Catovsky
- Monoclonal Gammopathies**
1437-1438 Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia
Cees G. Schaar, Henricus J. Vermeer, Pierre W. Wijermans, Wim Huisman, Saskia Le Cessie, Hanneke C. Kluin-Nelemans

Continuing Medical Education

- 1439 Post-remission treatment for high-risk adult acute lymphoblastic leukemia
- 1440 Combined therapy with deferiprone and desferrioxamine in thalassemia major
- 1440 Treatment of essential thrombocythemia